Fast Facts
Virtual company
- Lead product is a phase 2a compound for treatment of type 2 diabetes
- Stock is publicly traded as AKES.OB on the BB-OTC
- Strong business advisory team includes Kevin J. Kinsella (Avalon Ventures) and Kevin R. Sayer (brokered $3.8B acquisition of Minimed Inc. by Medtronic Inc.)
- Scientific Advisory Board:
- Christos Mantzoros, MD, DSc, Associate Professor of Medicine at Harvard Medical School, Associate Professor in Epidemiology at the Harvard School of Public Health
- Chris Orvig, Professor of Chemistry and Pharmaceutical Science, University of British Columbia
- John McNeil, Professor and Dean Emeritus, Pharmaceutical Sciences, University of British Columbia
- Michael Scaife, Ph.D., President, MChS Consulting Inc
Large Market Opportunity
- Approximately 20 million Americans have diabetes and more than 50 million have pre-diabetes according to recent NIH/CDC reports
- Market for oral diabetes drugs is estimated at $6 billion annually
Strong Pipeline
- AKP-020: (bis(ethylmaltolato)oxovanadium (IV), or BEOV) novel oral vanadium compound in-licensed from the University of British Columbia anticipated to begin Phase 1b/Phase 2a clinical trials after IND submission in 2007
- AKP-111 (metformin plus vanadyl sulfate and chromium picolinate) oral with human proof of concept data
- AKP-201 (glipizide plus chromium picolinate) - oral with human proof of concept data
- Strong patent estate including over 20 issued or filed patents
- Hundreds of published studies show the beneficial effects of chromium and/or vanadium on lowering blood sugar and stabilizing pancreatic beta-cells
